

Laurus Labs Limited
Corporate Office
2nd Floor, Serene Chambers, Road No. 7
Banjara Hills, Hyderabad - 500034, India
T +91 40 39804333 / 2342 0500 / 501
F +91 40 3980 4320



August 10, 2017

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS
--	---

Dear Sirs,


Sub: **Press Release**


Please find herewith the Press Release of the results of the Q1 of 2017-18.

Please take the information on record.

Thanking you,

Yours sincerely,
For Laurus Labs Limited


G. Venkateswar Reddy
Company Secretary



Registered Office : Plot No:21, J N Pharma City, Parawada, Visakhapatnam - 531021, India CIN: U24239AP2005PLC047518
T +91 891 3061222 F +91 891 3061270 E info@lauruslabs.com W lauruslabs.com

LAURUS Generics
Active Pharmaceutical Ingredients & Intermediates

LAURUS Ingredients
Specialty Ingredients for Nutraceutical & Allied Industry

LAURUS Synthesis
Contract Development & Manufacturing Services

LAURUS LABS CONTINUES TO MAINTAIN ITS GROWTH MOMENTUM

Q1 FY18 REVENUES UP BY 16.7%

Q1 FY18 EBITDA grows 19.5%

Q1 FY18 PAT grows 51.7%

Hyderabad, August 10, 2017: Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010), a leading research and development driven pharmaceutical company in India announces its Q1 FY18 results.

Q1 FY18 Laurus reported:

- Total net revenue improved 16.7% to Rs. 4,784 mn from Rs. 4,098 mn
- EBITDA showed growth of 19.5% to Rs. 1,035 mn as compared to Rs. 866 mn
- PAT showed growth of 51.7% to Rs. 389 mn from Rs. 256 mn
- EPS (Diluted) for the period stood at Rs. 3.7 per share (not annualised)

Commenting on the results announcement, Dr. Satyanarayana Chava - CEO said;

"Our Q1 FY 18 performance is along the expected lines, with good growth coming from our generic API portfolio, with in which Oncology portfolio showed robust growth and Hep C business continued its growth despite various challenges like GST. In our other businesses of Synthesis and Ingredients we have exceeded our growth expectations. Our pursuit of both newer geographies, including developed markets, new products introduced under Hepatitis C segment and other therapeutic areas are moving up the growth and also the focus on second line therapies has started yielding results.

FY18 is a landmark year as the scale up of our Aspen relationship takes place and contributes meaningfully to our performance. This planned diversification of business mix should bring clear visibility to growth initiatives.

As we continue to grow, the opportunities in select therapeutic areas are broadening. It remains an endeavor to leverage our deep domain expertise, state of the art research and manufacturing capabilities and our partnership model to introduce a best in class FDF business. We believe in a methodical integrated approach and are confident that as a full-fledged pharma company, we shall be able to meet the challenges that the generics industry faces today at the global level."

AUGUST 10, 2017

Press Release



10/10/17

Commenting on the results announcement, V V Ravi Kumar, ED & Chief Financial Officer said;

"We are happy to share the continuation of our growth story. Total revenues in Q1 FY 18 showed growth of 16%, shaped by contribution from APIs, viz; Oncology, Hep C and ARVs, along with the robust growth in Synthesis and Ingredients businesses.

The growth in EBIDTA margins during Q1 FY18 showing 20% YoY is promising and is underlined by initiatives taken for growth. The initiatives being taken in FDF and Synthesis will see introduction of a new line of products during the current year which will add to growth orientation and margins. As we move forward the business will also capture a better value from chosen therapeutic areas.

A stronger performance is expected to further strengthen our balance sheet and support the outlined growth initiatives. With a reduction in financing charges attained last fiscal we are hopeful that a strong growth in top line will supplement the drive growth in earnings."

Business Highlights:

Overall

- Total revenues grew by 16.7% in this quarter despite transition to GST.
- R & D Opex of INR 229 mn and 5% as percentage of sales during Q1 FY 18.
- Unit IV expansion is in progress, the facility will add capacity to Generics API, Synthesis & Ingredients business.
- Incorporated Laurus Holdings Limited (a 100% Subsidiary), in United Kingdom in the month of July 17
- Incorporated Laurus Generics Inc (a 100% Subsidiary) in USA for formulations business in the month of August 17.

Generic API

- Successfully completed the USFDA inspection for API facility in Unit 2 without any 483s observations.
- USFDA inspection for Unit 1&3 API is scheduled in August 2017.
- WHO inspection for unit 1&3 is scheduled in September 17.
- The Company has filed 211 patent applications and 45 patents granted as at June ended 2017.

Generic FDF

- Filed 4 ANDAs with USFDA, one dossier in Canada, one dossier in Europe and one dossier with WHO and completed 6 products validations.
- FDF Opex of INR 216 mn which includes INR 94 mn related to the R&D during Q1 FY 18.
- Capacity expansion to 5 bn units is in progress.

AUGUST 10, 2017

Press Release



Alireza
10/8/17

Synthesis

- Validations of 4 Products are on-going in Unit 5.

General

- Received Indian Innovation Award from Clarivate Analytics.
- Launched "Science on Wheels" as part of CSR, to promote Knowledge, a core value of Laurus Labs, on July 6 2017. This initiative will help in promoting science in Govt schools in Vizag rural areas.

-ENDS-

About Laurus Labs Limited

Laurus is a leading research and development driven pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus also manufactures APIs in Oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. Initiatives are in place to develop a Finished Dosages Forms capabilities on the back of existing strengths in APIs. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses. **Corporate Identification No: L24239AP2005PLC047518**

For more information about us, please visit <http://www.lauruslabs.com> or Contact particulars:

Pavan Kumar N

Laurus Labs Ltd.

Tel: +91 40 3980 4380/+919246564666

Email: mediarelations@lauruslabs.com

DISCLAIMER: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

AUGUST 10, 2017

Press Release

